1126795-15-0

Basic information

• Product Name: N₁-((1R,1'R,3R,3'R,5S,5'S)-[3,9'-bi(9'-azabicyclo[3.3.1]nonan)]-3'-yl)benzene-1,2-diamine
• Synonyms: N₁-((1R,1'R,3R,3'R,5S,5'S)-[3,9'-bi(9'-azabicyclo[3.3.1]nonan)]-3'-yl)benzene-1,2-diamine
• CAS NO: 1126795-15-0
• Molecular Weight: 353.551
• Mol File: 1126795-15-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: N₁-((1R,1'R,3R,3'R,5S,5'S)-[3,9'-bi(9'-azabicyclo[3.3.1]nonan)]-3'-yl)benzene-1,2-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N₁-((1R,1'R,3R,3'R,5S,5'S)-[3,9'-bi(9'-azabicyclo[3.3.1]nonan)]-3'-yl)benzene-1,2-diamine(1126795-15-0)
• EPA Substance Registry System: N₁-((1R,1'R,3R,3'R,5S,5'S)-[3,9'-bi(9'-azabicyclo[3.3.1]nonan)]-3'-yl)benzene-1,2-diamine(1126795-15-0)

Safety Data

• Hazardous Substances Data: 1126795-15-0(Hazardous Substances Data)

Upstream product

• 1126795-13-8 9-((exo)-bicyclo[3.3.1]nonan-3-yl)-9-azabicyclo[3.3.1]nonan-3-one 
• 95-54-5 1,2-diamino-benzene 
• 1126795-21-8 (1R,1'R,3R,3'R,5S,5'S)-N-(2-nitrophenyl)-9'-aza[3,9'-bi(bicyclo[3.3.1]nonan)]-3'-amine 
• 1384190-01-5 (1R,1'R,3R,3'R,5S,5'S)-9'-aza[3,9'-bi(bicyclo[3.3.1]nonan)]-3'-amine acetate 

Downstream Products

• 1616724-78-7 N₁-((1R,1'R,3r,3'R,5S,5'S,9's)-[3,9'-bi(bicyco[3.3.1]nonan)]-3'-yl)benzene-1,2-diamine 
• 1616724-07-2 2-((1R,1'R,3r,3'R,5S,5'S,9's)-[3,9'-bi(bicyclo[3.3.1]nonan)]-3'-yl(2-(carboxyformamido)phenyl)amino)-2-oxoacetic acid 
• 1616764-56-7 2-((2-((1R,1'R,3r,3'R,5S,5'S)-[3,9'-bi(9'-azabicyclo[3.3.1]nonan)]-3'-ylamino)phenyl)amino)-2-oxoethyl acetate 
• 1616764-52-3 ethyl 2-(3-(2-((1R,1'R,3r,3'R,5S,5'S)-[3,9'-bi(9'-azabicyclo[3.3.1]nonan)]-3'-ylamino)phenyl)ureido)acetate 

Relevant articles and documents

POLYMORPHIC FORMS OF A SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUND

Provided herein are novel crystalline forms of a crystalline compound of Formula (I), which modulates the ORL-1 receptor. The crystalline compounds of Formula (I), compositions thereof, and methods of using thereof that are described herein are particularly useful for treatment, prevention, and management of several sleep disorders.

CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF

The disclosure relates to Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein R1, R2, Qa, Y1, Z, A, B, Qx, E, G, J, M, U, W, and a are as defined herein, compositions comprising an effective amount of a Cyclic Urea- or Lactam-Substituted Quinoxal ine-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compound.

PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF

The disclosure relates to Phosphorus-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I), and pharmaceutically acceptable derivatives thereof wherein the dashed line, A, B, Q, R1, R2, R3, R4, Y1, Z, and a are as defined herein, compositions comprising an effective amount of a Phosphorus-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Phosphorus- Substituted Quinoxaline-Type Piperidine Compound.